pretranspl
screen
potenti
organ
donor
recipi
essenti
success
solid
organ
transplant
goal
pretranspl
infecti
diseas
screen
identifi
condit
may
disqualifi
either
donor
recipi
identifi
treat
activ
infect
pretranspl
defin
risk
infect
determin
strategi
prevent
mitig
posttranspl
infect
implement
prevent
intervent
updat
vaccin
statu
although
gener
agreement
major
infect
screen
perform
variat
center
type
screen
use
action
taken
result
cours
pretranspl
evalu
recipi
evalu
infect
risk
obtain
thorough
infect
travel
histori
well
histori
anim
environment
exposur
pretranspl
period
ideal
time
detail
counsel
recipi
hisher
famili
safe
food
handl
risk
infect
associ
pet
travel
hobbi
garden
woodwork
infect
prevent
approach
includ
hand
hygien
prophylact
antimicrobi
postexposur
prophylaxi
updat
immun
address
well
varieti
pathogen
may
transmit
transplant
tabl
guidelin
pretranspl
screen
subject
sever
public
includ
consensu
confer
immunocompromis
host
societi
ich
american
societi
transplant
ast
clinic
practic
guidelin
evalu
renal
transplant
candid
astp
clinic
practic
guidelin
evalu
live
renal
transplant
donor
recommend
regard
hepat
statu
donor
summar
march
crystal
citi
meet
review
chung
feng
delmonico
addit
center
diseas
control
prevent
cdc
infecti
diseas
societi
america
idsa
american
societi
blood
marrow
transplant
asbmt
publish
guidelin
prevent
infect
hematopoiet
stem
cell
transplant
recipi
cdc
publish
guidelin
prevent
hiv
transmiss
transplant
tradit
screen
strategi
effect
case
guarante
donorderiv
infect
number
highprofil
donorderiv
transmiss
incid
last
sever
year
includ
rabi
lymphocyt
choriomening
viru
west
nile
viru
wnv
hiv
hepat
c
hcv
renew
discuss
issu
surround
donor
screen
recent
form
unit
network
organ
share
uno
donor
transmiss
advisori
group
dtag
transplant
transmiss
sentinel
network
cdc
new
initi
form
address
donortransmit
infect
current
screen
practic
discuss
differ
screen
live
deceas
donor
review
summar
current
opinion
screen
bacteri
mycobacteri
fungal
parasit
viral
infect
donor
recipi
tabl
detail
discuss
infect
posttranspl
monitor
prophylaxi
treatment
found
section
guidelin
issu
concern
viral
serolog
donor
recipi
intertwin
discuss
togeth
given
limit
pool
donor
becom
necessari
consid
margin
candid
includ
infect
time
donat
higherrisk
serolog
profil
social
histori
indic
potenti
exposur
bloodborn
pathogen
hiv
hcv
natur
potenti
donor
infect
sever
endstag
organ
diseas
recipi
likelihood
anoth
organ
offer
patient
transplant
wait
list
import
consider
determin
accept
potenti
infect
donor
fischer
et
al
lung
transplant
deserv
special
attent
donor
bacteri
colon
common
lung
contact
extern
environ
mouth
upper
airway
site
colon
multipl
organ
donor
bronchoscopi
cultur
perform
time
evalu
andor
procur
allow
administr
antibiot
direct
colon
organ
prevent
invas
infect
recipi
iii
allograft
contamin
may
occur
procur
process
rubin
recommend
treatment
recipi
organ
isol
perfus
organ
transplant
medium
cite
risk
mycot
aneurysm
format
although
cultur
contamin
must
consid
well
activ
system
fungal
infect
donor
contraind
transplant
endem
mycos
particular
may
present
dormant
form
transmiss
histoplasmosi
transplant
describ
case
appear
result
reactiv
past
infect
recipi
mani
individu
midwestern
unit
state
calcifi
pulmonari
hilar
splenic
granulomata
xray
may
visibl
residua
old
histoplasma
infect
radiograph
sign
tradit
consid
contraind
donat
iii
transmiss
coccidioidomycosi
lung
transplant
report
southwestern
unit
state
although
reactiv
coccidioidomycosi
recipi
appear
far
common
yet
uniform
recommend
donor
screen
endem
mycos
emerg
toxoplasmosi
major
concern
particularli
heart
transplant
toxoplasmaseroneg
recipi
toxoplasmaseroposit
heart
highest
risk
develop
activ
toxoplasmosi
posttranspl
toxoplasmosi
also
rare
transmit
liver
kidney
recipi
donor
seroposit
contraind
heart
donat
allow
appropri
prophylaxi
administ
recipi
routin
trimethoprimsulfamethoxazol
prophylaxi
pneumocysti
jiroveci
effect
prevent
toxoplasmosi
may
negat
need
serolog
test
area
low
preval
screen
donor
toxoplasma
routin
perform
noncardiac
donor
may
part
screen
panel
center
state
discuss
issu
found
parasitolog
section
guidelin
follow
section
discuss
donor
recipi
screen
viral
infect
serolog
statu
donor
recipi
often
crucial
determin
risk
infect
tabl
virus
mention
discuss
detail
section
guidelin
transplant
although
hcv
recurr
common
posttranspl
patient
liver
graft
surviv
significantli
wors
pretranspl
diagnos
hcv
seroposit
renal
transplant
candid
higher
risk
liver
diseas
sepsi
transplant
hcv
seroneg
counterpart
compar
transplant
altern
balanc
benefit
often
fall
side
transplant
case
role
pretranspl
viral
load
reduct
studi
strategi
manag
hcv
recipi
discuss
detail
later
section
futur
rapid
molecular
test
like
increasingli
perform
time
frame
need
donor
evalu
compar
remain
wait
list
surviv
advantag
receiv
kidney
hcv
donor
thu
surviv
kidney
hcv
donor
less
seen
set
hcv
neg
donor
appear
associ
better
surviv
remain
dialysi
howev
one
seri
identifi
excess
rapidli
progress
cholestat
hepat
increas
mortal
overal
hcvrecipi
hcv
donor
heart
mycophenolatebas
immunosuppress
whether
specif
immunosuppress
regimen
prefer
situat
requir
studi
event
whenev
hcv
seroposit
donor
util
stringent
inform
consent
advis
recent
transmiss
event
proven
hcv
transmit
multipl
organ
tissu
transplant
recipi
seroneg
donor
complex
issu
involv
fulli
discuss
hiv
section
guidelin
also
concern
fals
posit
naat
may
result
loss
noninfect
organ
net
loss
life
particularli
liver
heart
candid
wait
list
region
canada
prospect
donor
test
wnv
naat
lymphocyt
choriomening
viru
lcmv
rodentassoci
arenaviru
report
sever
cluster
donorderiv
transmiss
multipl
organ
recipi
fatal
infect
one
cluster
outbreak
origin
new
pet
hamster
donor
home
strikingli
howev
donor
lcmv
serolog
neg
rais
question
kind
screen
measur
could
detect
prevent
transmiss
cdc
issu
interim
guidelin
minim
risk
lcmv
relat
pet
rodent
comprehens
report
system
introduc
cdc
recent
report
donorderiv
transmiss
new
relat
arenaviru
multipl
recipi
also
highlight
use
new
molecular
technolog
identif
unknown
pathogen
rabi
anoth
potenti
fatal
donorderiv
infect
recipi
transplant
donor
die
cerebr
hemorrhag
acquir
rapidli
progress
neurolog
ill
found
rabi
retrospect
donor
found
recent
bat
bite
recent
avail
igra
gener
interest
particularli
regard
patient
receiv
bacillu
calmetteguerin
bcg
vaccin
igra
assay
potenti
distinguish
ppd
posit
relat
bcg
relat
ltbi
isoniazid
hepatotox
appear
less
problem
origin
thought
transplant
candid
recipi
therefor
patient
histori
posit
ppd
radiograph
evid
prior
tb
previou
treatment
consid
isoniazid
prophylaxi
